Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.
Widely prescribed pain killers that provide relief with minimal side effects may have more pain-relieving properties than previously identified. A new study funded by the National Institute of Neurological Disorders and Stroke shows that non-steroidal anti-inflammatory drugs not only relieve pain at the local site of inflammation, but in fact affect the entire central nervous system.
NSAIDs reduce sensitivity of nerves in the central nervous system by inhibiting production of the COX-2 enzyme responsible for pain and inflammation.
A research team led by Clifford J. Woolf at Massachusetts General Hospital in Boston used an animal model to study COX-2's role in inflammatory pain. When inflammation occurred, researchers found COX-2 throughout the central nervous system, as well as at the local site of inflammation. They also found that inhibiting COX-2 production within the spinal cord and brain decreased pain and reduced hypersensitivity to normal sensations such as touch. Researchers now believe the widespread distribution of COX-2 within the central nervous system may contribute to the muscle and joint pain, depression, lethargy and loss of appetite that often occur with inflammation and infection.
"The findings indicate new treatment options for arthritis and other inflammatory pain conditions," said Cheryl A. Kitt, program director for pain research at the NINDS. "Targeting the central nervous system when using NSAIDs, rather than the specific peripheral pain site, may result in more effective pain relief." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo
November 11th 2024Results from the Phase II EMPOWER trial found that emraclidine failed to meet its primary endpoint of reducing Positive and Negative Syndrome Scale scores after six weeks of treatment for schizophrenia.